Can durvalumab cure lung cancer?
Results from a new clinical trial show that adding the immunotherapy drug durvalumab (Imfinzi) to chemotherapy can improve how long some people with small cell lung cancer live. UPDATE: On March 27, 2020, the Food and Drug Administration (FDA) approved durvalumab (Imfinzi) to treat small cell lung cancer (SCLC).
How successful is durvalumab?
Durvalumab Shows Significant Survival Benefit in Non-Small Cell Lung Cancer. Researchers estimate a 5-year overall survival rate of 42.9% for patients treated with durvalumab compared with 33.4% for those administered a placebo after chemoradiation therapy.
What is the pacific trial?
The “PACIFIC” trial (NCT02125461) (10) was a randomized, double-blind, phase 3 study comparing consolidation therapy with durvalumab versus placebo in patients with stage III, locally advanced, unresectable NSCLC that had not progressed after the standard treatment for stage III NSCLC (platinum-based CT/RT).
Is Tremelimumab approved?
Tremelimumab — which has no brand name yet — has not been approved by the U.S. Food and Drug Administration (FDA) to treat any cancer or disease. In April 2015, tremelimumab received orphan drug designation by the FDA to treat mesothelioma.
Can Stage 3B lung cancer go into remission?
Though stage 3 lung cancer is generally not considered curable, it is treatable. With the development of new and promising lung cancer treatments, more people may have a chance of achieving remission than ever before.
Is durvalumab FDA approved?
On March 27, 2020, the FDA approved durvalumab (IMFINZI, AstraZeneca) in combination with etoposide and either carboplatin or cisplatin as first-line treatment of patients with ES-SCLC based on an improvement in OS (Table 2).
Is durvalumab an immunotherapy?
Durvalumab is an immunotherapy treatment for bladder cancer and lung cancer. It is marketed under the brand name Imfinzi and manufactured by AstraZeneca. Durvalumab helps the immune system fight cancer, and clinical trials are testing it on a variety of diseases, including mesothelioma.
What are side effects of Durvalumab?
COMMON side effects
- constipation.
- urinary tract infection.
- low energy.
- fluid retention in the legs, feet, arms or hands.
- decreased appetite.
- trouble breathing.
- cough.
- nausea.
Is Durvalumab FDA approved?
When was Koselugo FDA approved?
Development Timeline for Koselugo
| Date | Article |
|---|---|
| Apr 13, 2020 | Approval FDA Approves Koselugo (selumetinib) for Pediatric Patients with Neurofibromatosis Type 1 Plexiform Neurofibromas |
Is there a global study for MEDI4736?
A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators.
How is MEDI4736 used in the treatment of cancer?
MEDI4736 is a human monoclonal antibody directed against programmed cell death ligand 1 (PD-L1). Signals from PD-L1 help tumours avoid detection by the immune system. MEDI4736 blocks these signals, countering the tumour’s immune-evading tactics. MEDI4736 is being developed to empower the patient’s immune system and attack the cancer.
What was the Pacific trial for durvalumab in NSCLC?
The PACIFIC trial was a Phase III, randomized, double-blinded, placebo-controlled, multi-center trial of durvalumab as a treatment in all-comer patients, regardless of PD-L1 status, with unresectable, Stage III NSCLC whose disease had not progressed following concurrent platinum-based CRT.
What are the goals of the Pacific trial?
The goal of the PACIFIC trial, the first study in the Phase III NSCLC programme, is to evaluate progression free survival and overall survival of MEDI4736 compared to placebo in patients with locally advanced, unresectable NSCLC (Stage III) following completion of treatment with chemoradiotherapy and no evidence of tumour progression.